Drugmaker Glenmark Prescribed drugs clocked a consolidated income of ₹3,387 crore for the three months ended December 31, 2024, up 35 per cent from ₹2,506 crore in the identical interval final yr.
The corporate clocked revenue after tax (PAT) for the quarter ended December 31, 2024 at ₹348 crore.
Glenn Saldanha, Chairman and Managing Director, Glenmark Prescribed drugs, stateditsdevelopment was pushed by efficiency throughout areas. “Our European enterprise continued to carry out properly, whereas our branded markets demonstrated resilient development. Strengthening our value-chain technique, we secured MHRA authorization for Winlevi within the UK, marking a pivotal step in increasing our dermatology portfolio,” he stated. “The North America enterprise is predicted to realize momentum from FY26 onwards, supported by our rising respiratory and injectable portfolio.,” he added.
- Additionally learn: Glenmark USA launches generic eye drops for Glaucoma therapy
Gross sales from the formulation enterprise in India in Q3 FY 2025 stood at ₹1,063 crore, as towards ₹265 crore within the earlier corresponding quarter, recording development of 300 per cent. North America registered revenues from the gross sales of completed dosage formulations of ₹781 crore, for the quarter ended Dec 31, 2024 as towards income of ₹770 crore for the earlier corresponding quarter, recording development of 1.4 per cent.
Giving an replace on its manufacturers, the corporate stated, advertising and marketing functions had been submitted in additional than 90 nations for Ryaltris, as of December 2024. The product had been commercialised in 43 markets, it added. The product is predicted to be launched in 12-15 further markets over the following few quarters, it added.
On Envafolimab, it stated, the product was being investigated in medical trials for extra most cancers indications, together with non-small cell lung most cancers, Glenmark plans to file Envafolimab in additional than 20 markets in FY25 and the primary market launch is predicted in FY26, it added.
Source link
#Glenmark #Pharma #clocks #PAT #crore
